COMMUNIQUÉS West-GlobeNewswire

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
14/05/2024
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
14/05/2024
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial funded by a NIAID [...]
Safety Shot Expands Operations to the Northeast
14/05/2024
The Company Will Launch in New York City, Long Island and The Hamptons Ahead of The Summer Months JUPITER, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company), announced today its [...]
STRATA Skin Sciences Surpasses 100 Domestic Installations of TheraClear®X Devices as of March 31, 2024
14/05/2024
HORSHAM, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and [...]
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
14/05/2024
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Ocugen Provides Business Update with First Quarter 2024 Financial Results
14/05/2024
Conference Call and Webcast Today at 8:30 a.m. ET All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License [...]
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
14/05/2024
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high [...]
Rani Therapeutics to Participate in May Investor Conferences
14/05/2024
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
14/05/2024
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human [...]
Simple HealthKit Honored in Health Services Category for Fast Company’s 2024 World Changing Ideas Awards
14/05/2024
From a solution to repurpose cold plasma to treat seeds to 3D printed living seawalls, the eighth annual awards honor new and inspiring solutions to the most daunting challenges of today FREMONT, Calif., May 14, 2024 ( [...]
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
14/05/2024
VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development of [...]
Clene to Present at Upcoming May Conferences
14/05/2024
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company [...]
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
14/05/2024
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE [...]
Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May
14/05/2024
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, May 14, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior [...]
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
14/05/2024
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate [...]
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
14/05/2024
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer ( [...]
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
14/05/2024
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
14/05/2024
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve [...]

Pages